Skip to main content
Premium Trial:

Request an Annual Quote

ImmunID, Singapore Immunology Network Collaborate on Immune Study

NEW YORK (GenomeWeb) – French immune molecular diagnostics firm ImmunID on Tuesday announced a deal with the Singapore Immunology Network (SigN) for research into immune competence.

Under the terms of the agreement, ImmunID will use its ImmunTracker and ImmunIG tests to evaluate T and B immune repertoire diversity in the blood of patients enrolled in a SigN-led clinical trial. The indication and therapeutic intervention being studied in the trial were not disclosed.

SigN is a research institute under Singapore's Agency of Science, Technology, and Research.

Anis Larbi, the principal investigator for the trial, said that ImmunID's technology broadens SigN's research efforts into the human immune system. "We can now get a more comprehensive understanding of it, using parameters such as immune repertoire diversity, which were neglected in the past," he said in a statement.

The project is for two years and will include 180 patients.

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.